CD44 and acute myeloid leukemia: To determine whether CD44 and CD162 were essential for binding of human AML cells to E-selectin, CRISPR-Cas9 gene editing was used to selectively suppress CD44 and/or CD162 genes (CD44 and SELPLG, respectively) from KG1a cells (representative cell surface CD44 and CD162 staining profiles after Crispr-Cas9 deletion shown in Figure 1D).